SEC For	rm 4																			
	FORM	4	UNITE	D STA	TES	s se	ECU					ANG	BE C	OMM	ISSION				1	
			Washington, D.C. 20549												OMB	APPRO	VAL			
Sectio obligat	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												OMB Number: 32 Estimated average burden hours per response:			
transa contra the pu securit intend defens	rchase or sale on ies of the issue ed to satisfy the	e pursuant to a r written plan for of equity r that is						,												
1. Name and Address of Reporting Person [*] Malik Fady Ibraham					2. Issuer Name and Ticker or Trading Symbol <u>CYTOKINETICS INC</u> [CYTK]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)										Image: Officer (give title below) Other (specify below) EVP Research & Development				specify	
350 OYSTER POINT BLVD																				
(Street) SOUTH SAN FRANCISCO CA 94080					4.1	Line)										oint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting				
(City)	(S	tate)	(Zip)												Perso	ו				
		Tab	le I - Noi	n-Deriv	ative	e Sec	curit	ies Ac	quired	, Dis	sposed	of, o	r Ber	neficial	ly Owned	ł				
D				2. Transa Date (Month/I	ar) if	2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Code (Instr.					Benefici	es	Form (D) o	: Direct r Indirect	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 11				11/12	/2024	4			М		5,30	0	А	\$7.9	6 120	120,220		D		
				11/12	/12/2024				S		5,30	0	D	\$58.4	´			D		
Common Stock 11/12				/2024	4			S		1,04	2	D	\$58.4	8 113	113,878		D			
		Ţ	Fable II -								osed of converti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr.		5. Number of		6. Date Exercisa Expiration Date (Month/Day/Yea		able and	7. Ti Amo Secu Unde Deri	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title		Amount or Number of Shares						
Non- Qualified Stock Option (Right to Buy)	\$7.96	11/12/2024			М			5,300	03/26/20	15	02/26/2025		nmon ock	5,300	\$0	10,60	0	D		

Explanation of Responses:

/s/ Robert Wong, attorney-infact for Dr. Malik

11/13/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.